Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study

CONCLUSION: In Swiss clinical practice, evolocumab was mainly prescribed to patients with very high cardiovascular risk, who had very high LDL-C levels. Most patients continued to use evolocumab throughout the study period. In these patients, LDL-C was reduced by >50% within 3 months and LDL-C reductions were maintained over time. Guideline-recommended LDL-C goals for this very high-risk cohort were more frequently attained in patients receiving a combination of statin and/or ezetimibe and evolocumab.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02770131.PMID:38183273 | PMC:PMC10771737 | DOI:10.1177/17539447231213288

Source: Adv Data - January 6, 2024 Category: Epidemiology Authors: Isabella Sudano Stephan Kr ähenbühl Fran çois Mach Anne Anstett Nafeesa Dhalwani Ian Bridges Mahendra Sibartie Kausik K Ray Source Type: research